Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific aortic valve stenosis, but no approved specific therapy exists to substantially lower Lp(a) concentrations. We aimed to assess the efficacy, safety, and tolerability of two unique antisense oligonucleotides designed to lower Lp(a) concentrations.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet

Title: Lancet (London, England)

Publisher: Elsevier BV

ISSN (Electronic): 1474-547X

ISSN (Print): 0140-6736

Publication date (Electronic): Nov 05 2016

Volume: 388

Issue: 10057

Affiliations

[1 ] Ionis Pharmaceuticals, Carlsbad, CA, USA.

[2 ] Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands; Department of Molecular Cell Biology, Sanquin, Amsterdam, Netherlands.

[3 ] University of Washington, Seattle, WA, USA.

[4 ] University of California San Diego, La Jolla, CA, USA.

[5 ] Department of Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands.

[6 ] Ionis Pharmaceuticals, Carlsbad, CA, USA; University of California San Diego, La Jolla, CA, USA. Electronic address: stsimikas@ucsd.edu.

Article

Publisher Item ID: S0140-6736(16)31009-1

DOI: 10.1016/S0140-6736(16)31009-1

PubMed ID: 27665230

SO-VID: c15cae7c-9ef3-4990-ae14-0aa1d6623d3e

History

Data availability:

Comments

Comment on this article

scite_

Cited by 249

See all cited by

- Version 1